| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 15 | 2025 | 102 | 2.880 |
Why?
|
| Breast Neoplasms | 19 | 2025 | 2759 | 2.020 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2025 | 820 | 1.180 |
Why?
|
| Estrogen Receptor alpha | 6 | 2023 | 473 | 0.980 |
Why?
|
| Receptors, Estrogen | 6 | 2025 | 823 | 0.830 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 271 | 0.730 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2025 | 266 | 0.710 |
Why?
|
| Endocytosis | 3 | 2011 | 131 | 0.700 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2025 | 50 | 0.640 |
Why?
|
| Proteomics | 12 | 2025 | 589 | 0.640 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2025 | 67 | 0.640 |
Why?
|
| Neoplasms | 6 | 2024 | 3008 | 0.630 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1846 | 0.590 |
Why?
|
| Gene Fusion | 1 | 2018 | 61 | 0.580 |
Why?
|
| Receptors, Interleukin-5 | 2 | 2008 | 5 | 0.570 |
Why?
|
| Neurofibromin 1 | 3 | 2025 | 48 | 0.450 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1714 | 0.430 |
Why?
|
| Signal Transduction | 9 | 2025 | 4883 | 0.430 |
Why?
|
| Lysine | 2 | 2011 | 204 | 0.410 |
Why?
|
| Ubiquitination | 2 | 2021 | 180 | 0.390 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2011 | 1 | 0.380 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 11 | 0.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 248 | 0.380 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 131 | 0.340 |
Why?
|
| Eosinophils | 2 | 2008 | 128 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 3 | 2024 | 406 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 608 | 0.320 |
Why?
|
| Precision Medicine | 2 | 2023 | 355 | 0.310 |
Why?
|
| Transferrin | 1 | 2008 | 50 | 0.300 |
Why?
|
| Mutation | 9 | 2025 | 6274 | 0.290 |
Why?
|
| src-Family Kinases | 2 | 2016 | 98 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 403 | 0.280 |
Why?
|
| Humans | 41 | 2025 | 133455 | 0.280 |
Why?
|
| Protein Kinases | 3 | 2025 | 341 | 0.280 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 3725 | 0.280 |
Why?
|
| Janus Kinases | 1 | 2007 | 33 | 0.270 |
Why?
|
| Ubiquitin | 1 | 2007 | 147 | 0.250 |
Why?
|
| Female | 27 | 2025 | 71472 | 0.250 |
Why?
|
| Receptor, ErbB-2 | 3 | 2025 | 559 | 0.240 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 9 | 0.240 |
Why?
|
| Software | 3 | 2025 | 735 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 91 | 0.230 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 15 | 0.230 |
Why?
|
| Phosphoproteins | 2 | 2025 | 453 | 0.230 |
Why?
|
| Phosphorylation | 6 | 2025 | 1699 | 0.230 |
Why?
|
| Down-Regulation | 1 | 2007 | 715 | 0.220 |
Why?
|
| Benzamides | 1 | 2024 | 125 | 0.210 |
Why?
|
| Nitriles | 1 | 2024 | 155 | 0.210 |
Why?
|
| Paclitaxel | 1 | 2024 | 142 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 990 | 0.210 |
Why?
|
| Computational Biology | 2 | 2025 | 886 | 0.210 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2025 | 382 | 0.210 |
Why?
|
| Cell Proliferation | 5 | 2025 | 2536 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1791 | 0.200 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 114 | 0.190 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 73 | 0.190 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 680 | 0.190 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 369 | 0.190 |
Why?
|
| Proteome | 1 | 2023 | 281 | 0.180 |
Why?
|
| Metformin | 1 | 2023 | 162 | 0.180 |
Why?
|
| Machine Learning | 1 | 2024 | 325 | 0.180 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 433 | 0.180 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2025 | 555 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1911 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 233 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1352 | 0.160 |
Why?
|
| Prognosis | 3 | 2025 | 5058 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 2114 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 132 | 0.160 |
Why?
|
| Claudins | 1 | 2018 | 31 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2024 | 1243 | 0.150 |
Why?
|
| Genomics | 4 | 2023 | 1671 | 0.150 |
Why?
|
| Mitosis | 1 | 2018 | 194 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 871 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2025 | 1069 | 0.140 |
Why?
|
| MutL Proteins | 1 | 2017 | 14 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 38 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 363 | 0.140 |
Why?
|
| Protein Binding | 3 | 2021 | 1832 | 0.130 |
Why?
|
| Transfection | 1 | 2018 | 1086 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 398 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2018 | 423 | 0.120 |
Why?
|
| Mammary Glands, Human | 1 | 2016 | 83 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 873 | 0.120 |
Why?
|
| Cell Movement | 1 | 2018 | 916 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2021 | 775 | 0.110 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 231 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1021 | 0.110 |
Why?
|
| Pyridines | 2 | 2025 | 247 | 0.100 |
Why?
|
| Piperazines | 2 | 2025 | 257 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1405 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 21664 | 0.100 |
Why?
|
| Immunotherapy | 3 | 2024 | 744 | 0.100 |
Why?
|
| Animals | 10 | 2025 | 36278 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 665 | 0.090 |
Why?
|
| Mice | 7 | 2025 | 18818 | 0.090 |
Why?
|
| Endosomes | 1 | 2011 | 68 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 387 | 0.080 |
Why?
|
| Middle Aged | 7 | 2025 | 29299 | 0.080 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2008 | 6 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 808 | 0.080 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 9 | 0.080 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 13 | 0.070 |
Why?
|
| Clathrin | 1 | 2008 | 25 | 0.070 |
Why?
|
| Cholera Toxin | 1 | 2008 | 52 | 0.070 |
Why?
|
| Interleukin-5 | 1 | 2008 | 48 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2023 | 626 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 161 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12987 | 0.070 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 58 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2007 | 13 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2021 | 303 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2899 | 0.060 |
Why?
|
| Apoptosis | 2 | 2024 | 1931 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 485 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2007 | 302 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2008 | 836 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 270 | 0.060 |
Why?
|
| Databases, Protein | 1 | 2025 | 62 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 790 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2025 | 78 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2025 | 63 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 123 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7183 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 790 | 0.060 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 45 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2025 | 154 | 0.060 |
Why?
|
| Protein Interaction Maps | 1 | 2024 | 89 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 254 | 0.050 |
Why?
|
| Benchmarking | 1 | 2025 | 149 | 0.050 |
Why?
|
| Phosphopeptides | 1 | 2023 | 28 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 605 | 0.050 |
Why?
|
| Knowledge Bases | 1 | 2023 | 39 | 0.050 |
Why?
|
| Adult | 5 | 2024 | 31881 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 230 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4745 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 54 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 92 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 178 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 119 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2025 | 242 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 24 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2023 | 124 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 87 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 118 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 396 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 229 | 0.050 |
Why?
|
| Cell Division | 1 | 2023 | 773 | 0.050 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2021 | 21 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 407 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 157 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2834 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1532 | 0.050 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2021 | 35 | 0.050 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 182 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2007 | 3162 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 508 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 86 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 861 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5176 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 438 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 38 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1101 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 201 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 105 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 352 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 39 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 144 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 139 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 27 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 27 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1153 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 72 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2018 | 39 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 610 | 0.040 |
Why?
|
| Vimentin | 1 | 2018 | 70 | 0.040 |
Why?
|
| Male | 5 | 2025 | 65713 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2020 | 376 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 194 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1063 | 0.040 |
Why?
|
| Algorithms | 1 | 2025 | 1724 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 395 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 542 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2020 | 687 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 79 | 0.030 |
Why?
|
| DNA Repair | 1 | 2020 | 628 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 455 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 716 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 397 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 26 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2199 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 497 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 362 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2235 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 90 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1070 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 123 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 161 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 336 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1605 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1122 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 351 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2018 | 867 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 315 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 664 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1756 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6649 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1334 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2008 | 40 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 45 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 69 | 0.020 |
Why?
|
| Turner Syndrome | 1 | 2008 | 46 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 324 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 360 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 9881 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 833 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 2804 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 14758 | 0.010 |
Why?
|